Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06859762 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 19
- Study locations
NCT06859762 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 220 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (15% higher). The trial reports 19 study locations across 17 states.
The verdict
NCT06859762, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 19
- Study locations
Study Summary
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
Conditions Studied
Interventions
- DRUG YL217
Study Locations (19)
Ohio
- University of Cincinnati Medical Center - Cincinnati
- Cleveland Clinic Taussig Cancer Institute - Cleveland
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- UT Health San Antonio - Mays Cancer Center - San Antonio
Arizona
- Mayo Clinic Arizona - Phoenix
California
- UCLA Hematology/Oncology - Santa Monica - Santa Monica
Connecticut
- Yale Cancer Center - New Haven
Kansas
- The University of Kansas Cancer Center (KUCC) - Kansas City
Maryland
- University of Maryland Medical Center-Greenebaum Cancer Ctr - Medical Oncology - Baltimore
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06859762
The ClinicalTrials.gov registry entry for NCT06859762 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (15% higher). The listed sponsor is MediLink Therapeutics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which YL217 is the first listed.
NCT06859762 reports 19 study locations spanning 17 distinct geographic areas - top geographies include Ohio, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT06859762 about?
NCT06859762 is a clinical study titled "A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors". A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
What is the current status of trial NCT06859762?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2025-07-02. Estimated completion is 2027-07.
What conditions does trial NCT06859762 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06859762?
The interventions under investigation include: YL217 (DRUG).
Who is sponsoring clinical trial NCT06859762?
This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06859762 being conducted?
This trial has 19 study locations across Arizona, California, Connecticut, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.